RespireRx Pharmaceuticals Inc (fka RSPI)

[Aiming4]

Dew's post on Ampakine platform from a few days ago... #Msg-23607298

Dew posted this last Thursday after the IND decision, it's another viewpoint and opinion that the Ampakine platform could be in question. I disagree with the conclusion, but Dew has summarized some good points to think about and it makes a companion piece to the Yale Asst. Professor's comments... Aiming4.

COR addendum:

I think it’s reasonable to say that COR’s entire low-impact Ampakine platform is in doubt. Let’s recap:

COR’s first attempt was in mild cognitive impairment (MCI) and that effort failed. The failure was blamed on poor pharmacokinetics of an older drug in the platform, but there was no attempt to resuscitate the MCI program by using a drug with better PK. Instead, the indication was simply dropped.

COR’s next effort was in excessive daytime sleepiness (EDS) and that effort failed. The failure was blamed on poor trial design, but there was no attempt to resuscitate the EDS program by using a better trial design Instead, the indication was simply dropped.

COR’s latest effort was in ADHD and that effort initially appeared to be a modest success. However, the FDA cited safety issues with the drug, and the program’s failure is now being blamed (by posters on the COR iHub board) on… politics! Evidently, there will be no attempt to resuscitate the ADHD program; instead, the indication will simply be dropped.

Now management says the best-suited indication for low-impact Ampakines is respiratory depression (RD), which had never even been mentioned to investors until a few months ago.

In summary, the lead indication has bounced around from MCI to EDS to ADHD to RD and there is yet to be any indication where any COR drug is effective and safe enough to continue testing.

It looks to me as though COR’s low-impact Ampakines are a dubious platform desperately seeking some indication. In other words, Zebra’s Law appears to be in play.